Core Viewpoint - Enlivex Therapeutics has successfully listed its primary treasury asset, the RAIN token, on the WhiteBIT cryptocurrency exchange, enhancing market access and liquidity for the token [1][2]. Group 1: Company Overview - Enlivex Therapeutics is a clinical stage company focused on macrophage reprogramming immunotherapy, particularly in the late-stage clinical development of Allocetra™, aimed at treating osteoarthritis [4]. - The company has developed a treasury strategy centered on RAIN, which serves as its primary treasury reserve asset, providing investors with exposure to digital capital [4]. Group 2: RAIN Token and Market Strategy - The RAIN token is the governance and utility token of a decentralized predictions and options protocol on the Arbitrum network, allowing users to create and trade markets tied to real-world events [3]. - The listing of RAIN on WhiteBIT, the largest European cryptocurrency exchange by traffic, is expected to broaden regional market access and enhance secondary market liquidity, supporting the development of market infrastructure for Enlivex's digital asset strategy [2]. Group 3: Osteoarthritis Market Context - Osteoarthritis affects over 32.5 million Americans and more than 300 million individuals globally, with projections indicating that 78 million Americans will have the condition by 2040 [5]. - The burden of osteoarthritis is significant, leading to over one million hospitalizations annually in the U.S., primarily for total joint replacement, highlighting the critical need for effective treatments [5].

Core Viewpoint - Enlivex Therapeutics Ltd. has announced its decision to voluntarily delist its ordinary shares from the Tel Aviv Stock Exchange (TASE) to focus on U.S.-based trading and reduce administrative costs associated with dual listing [1][4]. Group 1: Delisting Process - The last trading day for the ordinary shares on the TASE is expected to be April 23, 2026, with delisting anticipated around April 26, 2026 [2]. - Shareholders will continue to trade ordinary shares on the TASE until the final trading day [2]. - The ordinary shares will continue to be traded on the Nasdaq Capital Market under the symbol "ENLV" [3]. Group 2: Strategic Objectives - The Board of Directors approved the delisting to operate under a single set of listing requirements, which aims to reduce duplicative administrative costs and potentially enhance liquidity on Nasdaq [4]. - The transition allows the company to concentrate its investor and public relations efforts on the U.S. capital markets [4]. Group 3: Company Overview - Enlivex is a clinical-stage biotech company focused on macrophage reprogramming immunotherapy, particularly in the late-stage clinical development of Allocetra™, a therapy for osteoarthritis [5]. - Osteoarthritis affects over 32.5 million Americans and is projected to impact 78 million by 2040, highlighting a significant market need for effective treatments [6].

Group 1 - Enlivex Therapeutics Ltd. reported the listing of its treasury asset, the RAIN token, on the KuCoin cryptocurrency exchange, effective January 6, which is expected to enhance global market access and liquidity for the token [1] - The company has launched a digital asset treasury strategy focused on acquiring RAIN tokens, which serve as the governance and utility token for a decentralized predictions-and-options protocol on the Arbitrum network [2] - Enlivex plans to utilize proceeds from a private investment in public equity of 212 million shares at $1.00 per share to implement the RAIN prediction markets token treasury strategy while maintaining focus on core business operations [3] Group 2 - HC Wainwright highlighted the potential growth trajectory of the RAIN token, referencing precedent cases like Polymarket and Kalshi, which reached an $11 billion valuation, indicating a promising future for prediction markets [4] - If prediction markets achieve $1 trillion in annual volume within five years and RAIN captures a 5% market share, approximately $1.25 billion of RAIN tokens would be purchased and burned in that year alone, with additional tokens burned from cumulative trading volume [5] - These dynamics are expected to significantly reduce token supply, increase daily trading activity, and exert upward pressure on the RAIN token price, leading to an updated price forecast from $7 to $13 by HC Wainwright [6] Group 3 - The update on Enlivex's valuation reflects dilution from the recent PIPE transaction and incorporates the value of RAIN tokens on the balance sheet, along with an updated valuation of the company's Allocetra clinical programs in osteoarthritis [7] - As of the last check, ENLV stock is up 4.52% at $0.93 [7]

Core Viewpoint - Enlivex Therapeutics has successfully listed its primary digital treasury asset, the RAIN token, on the KuCoin cryptocurrency exchange, enhancing market access and liquidity for the token [1][2]. Group 1: Company Overview - Enlivex Therapeutics is the first publicly-listed company to develop a treasury strategy centered on the RAIN token, which serves as its primary treasury reserve asset [4]. - The company is also engaged in the late-stage clinical development of Allocetra™, a novel therapy for osteoarthritis, a condition affecting over 32.5 million Americans and more than 300 million people globally [5]. Group 2: RAIN Token and Digital Asset Strategy - The RAIN token is the governance and utility token of a decentralized predictions and options protocol built on the Arbitrum network, allowing users to create and trade markets tied to real-world events [3]. - The listing of RAIN on KuCoin is expected to significantly enhance global market access and secondary liquidity for Enlivex's digital asset treasury [2][3]. Group 3: KuCoin Exchange - KuCoin is a leading global cryptocurrency exchange with over 40 million users, primarily in Southeast Asia, and ranks among the top ten cryptocurrency exchanges worldwide [2]. - The exchange offers a comprehensive suite of trading products, including spot trading, derivatives, and yield services, which will benefit the trading of RAIN [2].

Investment in the Company is subject to significant risks and should only be made after a careful review of the relevant documentation and following the consultation of a legal, tax or other adviser. Investing in the Company is speculative, not suitable for all investors, and intended only for investors who are able to bear the high economic risks of such investment, which can include, but are not limited to, loss of all or a substantial portion of your investment. Each prospective purchaser should carefull ...

Core Insights - Enlivex Therapeutics Ltd. will host a virtual fireside chat on December 11, 2025, to discuss its recent $212 million private placement and future plans [1][2][3] - The company is focusing on advancing the clinical development of Allocetra™, a therapy for osteoarthritis, which affects over 32.5 million Americans and 300 million people globally [5] Company Plans - Shai Novik, Executive Chairman, will provide updates on the digital asset treasury strategy centered around RAIN token accumulation [2] - Enlivex aims to offer investors exposure to RAIN as a primary treasury reserve asset [4] Clinical Development - Allocetra™ is designed to treat osteoarthritis, a prevalent joint disease with significant hospitalization rates in the U.S. [5] - There are currently no FDA or EMA approved medications that can halt or reverse joint damage in osteoarthritis patients [5]

Core Insights - Enlivex has implemented the world's first RAIN prediction markets token digital asset treasury strategy through RAIN token accumulation [1][3][7] - The company is focused on the clinical development of Allocetra, a novel therapy for knee osteoarthritis, addressing a significant unmet medical need in a growing market [2][8] Company Developments - Enlivex has closed a $212 million private investment, with plans to utilize the proceeds for the RAIN prediction markets token treasury strategy while maintaining its core business operations [3][7] - Former Italian Prime Minister Matteo Renzi has joined the Board of Directors, emphasizing the importance of responsible innovation and the potential of blockchain technologies [5] RAIN Protocol Overview - RAIN is a decentralized predictions and options protocol built on the Arbitrum network, allowing users to create and trade custom options on various markets [4] - The protocol features a deflationary Buyback & Burn mechanism and aims to be a leading platform for prediction markets, promoting transparency and community participation [4] Market Context - Osteoarthritis affects over 32.5 million Americans and more than 300 million people globally, with a projected increase to 78 million Americans by 2040 [8] - There are currently no FDA or EMA approved medications that can effectively halt or reverse the progression of joint damage in osteoarthritis patients, highlighting a critical need for effective treatments [8]

Market Performance - U.S. stocks experienced an upward trend, with the Nasdaq Composite increasing by over 500 points on Monday. The Dow rose by 0.65% to 46,546.82, the NASDAQ increased by 2.32% to 22,789.25, and the S&P 500 gained 1.40% to 6,696.44 [1] - Communication services stocks saw a significant rise of 3.1% on the same day, while consumer staples stocks fell by 1.1% [2][1] Economic Indicators - The Dallas Fed's general business activity index for Texas manufacturing dropped to -10.4 in November, down from -5 in the previous month, indicating a decline in manufacturing activity [3][11] Commodity Prices - In commodity markets, oil prices increased by 0.1% to $58.13, gold rose by 0.2% to $4,089.00, silver gained 0.4% to $50.105, while copper fell by 0.8% to $4.9745 [6] International Markets - European shares showed positive movement, with the eurozone's STOXX 600 rising by 0.44%, Spain's IBEX 35 Index increasing by 1.19%, and other major indices in London, Germany, and France also experiencing gains [7] - Asian markets had mixed results, with Hong Kong's Hang Seng gaining 1.97%, China's Shanghai Composite slightly up by 0.05%, and India's BSE Sensex declining by 0.39% [8] Company News - Enlivex Therapeutics Ltd. saw its shares surge by 48% to $1.3301 following a $212 million private placement announcement [10] - Oscar Health, Inc. shares rose by 21% to $16.38 after news of a proposed two-year extension of Obamacare subsidies [10] - Inno Holdings Inc. experienced a significant increase of 169% to $1.9499 after announcing a strategic cooperation on Web3 Technology [10] - Waldencast plc shares dropped by 12% to $2.7095 after releasing second-quarter results [10] - Twin Hospitality Group Inc. shares fell by 28% to $2.5700 due to a notice of acceleration for notes [10] - ProMIS Neurosciences, Inc. shares decreased by 19% to $0.3399 following a 1-for-25 reverse stock split announcement [10]

Core Insights - Enlivex Therapeutics Ltd. announced a private placement of $212 million to initiate a digital asset treasury strategy centered around RAIN token accumulation [2][7] - The company appointed Matteo Renzi, former Prime Minister of Italy, to its board of directors, effective November 24, 2025 [1][4] Financial Details - The private investment in public equity (PIPE) involves the purchase of 212 million ordinary shares at $1.00 per share, representing an 11.5% premium from the closing price on November 21, 2025 [2] - The expected aggregate gross proceeds from this transaction are approximately $212 million, funded in a combination of USD and USDT [2] Business Strategy - Enlivex aims to implement the first RAIN prediction markets token treasury strategy while maintaining focus on its core business operations [2][7] - The RAIN protocol is designed to be a decentralized predictions and options platform, allowing users to create and trade custom options on various markets [3] Market Context - Enlivex will be the first publicly-listed company to adopt a treasury strategy centered on RAIN, positioning itself to provide investors with exposure to this digital asset [7] - The company is also focused on the late-stage clinical development of AllocetraTM, a novel therapy for osteoarthritis, which affects over 32.5 million Americans and 300 million individuals globally [8]

Market Overview - U.S. stocks experienced an upward trend, with the Nasdaq Composite increasing by over 350 points on Monday. The Dow rose by 0.16% to 46,318.84, the NASDAQ increased by 1.60% to 22,629.51, and the S&P 500 gained 0.83% to 6,658.09 [1] - Communication services sector saw a significant rise of 2.7% on Monday, indicating strong performance in that area [1] Sector Performance - Energy stocks declined by 0.9% during trading on Monday, reflecting a downturn in that sector [2] Company Earnings - CureVac N.V. reported third-quarter earnings of $1.41 per share, surpassing the analyst consensus estimate of a loss of $0.17 per share. The company also reported quarterly sales of $63.295 million, exceeding the analyst consensus estimate of $14.520 million [3] Commodities - In commodity trading, oil prices increased by 0.1% to $58.07, while gold prices decreased by 0.1% to $4,078.40. Silver and copper also saw slight declines of 0.1% and 0.4%, trading at $49.875 and $4.9935 respectively [6] Company Stock Movements - Enlivex Therapeutics Ltd. shares surged by 79% to $1.61 following the announcement of a $212 million private placement [10] - Inspire Veterinary Partners, Inc. shares rose by 51% to $0.1836 [10] - Inno Holdings Inc. shares increased by 44% to $1.04 after announcing a strategic cooperation with Megabyte Solutions [10] - Clearside Biomedical, Inc. shares plummeted by 67% to $0.8799 after filing for voluntary bankruptcy [10] - Twin Hospitality Group Inc. shares fell by 28% to $2.5700 due to a notice of acceleration for notes [10] - ProMIS Neurosciences, Inc. shares decreased by 25% to $0.3157 following a 1-for-25 reverse stock split announcement [10] International Markets - European shares showed positive movement, with the eurozone's STOXX 600 rising by 0.2%, Spain's IBEX 35 Index increasing by 0.8%, and other major indices also experiencing gains [7] - Asian markets had mixed results, with Hong Kong's Hang Seng gaining 1.97% and India's BSE Sensex declining by 0.39% [8]